Infliximab

Active ingredient description

Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFβ).

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L04AB02 Infliximab L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
Discover more medicines within L04AB02

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
AVSOLA Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
ZESSLY Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

External identifiers

CAS Substance: 170277-31-3
DrugBank Drug: DB00065
RxNorm Ingredient: 191831
SNOMED-CT Concept: 386891004
Infliximab (substance)
UNII Identifier: B72HH48FLU
INFLIXIMAB

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.